Secukinumab

Product Name: Secukinumab
CAS No.: 1229022-83-6
Chemical Name: Secukinumab
Synonyms: AIN457;AIN 457;AIN-457;Secukinumab;Secukinumab (anti-IL-17A);Research Grade Secukinumab;Research Grade Secukinumab(DHH28802)
CBNumber: CB12744217
Formula Weight: 0
MOL File: Mol file

More

Less

Secukinumab Property

form: Liquid
color: Colorless to light yellow
CAS DataBase Reference: 1229022-83-6

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Secukinumab Chemical Properties,Usage,Production

Uses

Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].

Clinical Use

Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis

Drug interactions

Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live vaccines - avoid.

IC 50

IL-17A

Metabolism

The majority of IgG elimination occurs via intracellular catabolism, following fluid-phase or receptor mediated endocytosis.

References

[1] Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. DOI:10.1007/s40265-016-0602-3
[2] Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. DOI:10.1007/s40265-016-0602-3
[3] Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. DOI:10.1002/glia.22637

Secukinumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Secukinumab Suppliers

China 39 United States 3 Global 42

Wuhan Sunrise Technology Development Co., Ltd.

Tel: 27-027-83314682 13554138826
Fax: +86 (27) 8331-4682
Email: whsrtech@vip.163.com
Country: China
ProdList: 246
Advantage: 62

BOC Sciences

Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Country: United States
ProdList: 12952
Advantage: 65

Sichuan Wei Keqi Biological Technology Co., Ltd.

Tel: 028-81700200 18116577057
Fax: 028-81705658
Email: 3003855609@qq.com
Country: China
ProdList: 7778
Advantage: 56

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4757
Advantage: 55

Shanghai Hanjing Chemicals Co., Ltd.

Tel: 021-54285032 13641685631
Fax: +86 (21) 5443 7651
Email: gerry.shu@hanjingchemicals.com
Country: China
ProdList: 76
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9803
Advantage: 58

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

Shanghai Rechem science Co., Ltd.

Tel: 021-31433387 15618786686
Fax: QQ:1369748377
Email: sales@rechemscience.com
Country: China
ProdList: 2989
Advantage: 58

Hefei Hirisun Pharmatech Co., Ltd.

Tel: +86-0551-62678551 +86-15056975894
Fax: 05512678551
Email: sales@hirisunpharm.com
Country: China
ProdList: 176
Advantage: 55

Taizhou Crene Biotechnology Co. Ltd.

Tel: +86-0576-88813233 +86-13396860566
Email: sales@pharm-intermediates.com
Country: China
ProdList: 1991
Advantage: 58

1229022-83-6, SecukinumabRelated Search:

Ixekizumab ibritumomab tiuxetan Evolocumab Oleclumab Brodalumab Briakinumab Brazikumab Ustekinumab guselkumab Mirikizumab

Secukinumab

Research Grade Secukinumab(DHH28802)

AIN 457

AIN457

AIN-457

Secukinumab (anti-IL-17A)

Research Grade Secukinumab

1229022-83-6